Evidence map›Paper›PMID 39234802›Full record

ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2024

Diagnostic performance of central vein sign versus oligoclonal bands for multiple sclerosis.

Karlo Toljan, Lynn Daboul, Praneeta Raza, Melissa L Martin, Quy Cao, Carly M O'Donnell, Paulo Rodrigues, John Derbyshire, Christina J Azevedo, Amit Bar-Or and 18 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Karlo ToljanDepartment of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0002-3189-9659
Lynn DaboulTranslational Neuroradiology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
Praneeta RazaMellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.
Melissa L MartinDepartment of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Quy CaoDepartment of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-6204-1305
Carly M O'DonnellDepartment of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Paulo RodriguesQMENTA, Boston, MA, USA.
John DerbyshireFunctional MRI Facility, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.
Christina J AzevedoDepartment of Neurology, University of Southern California, Los Angeles, CA, USA.ORCID 0000-0002-8622-1845
Amit Bar-OrDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0001-7179-0335
Eduardo CaverzasiWeill Institute for Neurosciences, Department of Neurology, University of California at San Francisco, San Francisco, CA, USA.ORCID 0000-0002-0350-0460
Peter A CalabresiDepartment of Neurology, Johns Hopkins University, Baltimore, MD, USA.ORCID 0000-0002-7776-6472
Bruce Ac CreeWeill Institute for Neurosciences, Department of Neurology, University of California at San Francisco, San Francisco, CA, USA.ORCID 0000-0001-7689-2533
Leorah FreemanDepartment of Neurology, Dell Medical School, University of Texas at Austin, Austin, TX, USA.
Roland G HenryWeill Institute for Neurosciences, Department of Neurology, University of California at San Francisco, San Francisco, CA, USA.
Erin E LongbrakeDepartment of Neurology, Yale University, New Haven, CT, USA.
Jiwon OhDivision of Neurology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.ORCID 0000-0001-5519-6088
Nico PapinuttoWeill Institute for Neurosciences, Department of Neurology, University of California at San Francisco, San Francisco, CA, USA.
Daniel PelletierDepartment of Neurology, University of Southern California, Los Angeles, CA, USA.
Rohini D SamudralwarDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Matthew K SchindlerDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Elias S SotirchosDepartment of Neurology, Johns Hopkins University, Baltimore, MD, USA.ORCID 0000-0002-8812-1637
Nancy L SicotteDepartment of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Andrew J SolomonDepartment of Neurological Sciences, Larner College of Medicine, University of Vermont, Burlington, VT, USA.ORCID 0000-0003-1602-1554
Russell T ShinoharaDepartment of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Daniel S ReichTranslational Neuroradiology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-2628-4334
Pascal SatiTranslational Neuroradiology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-6763-0125
Daniel OntanedaMellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0002-2838-9148

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Multimodal MRI in Multiple SclerosisZIANS003119 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI REICH, DANIEL · 2010 to 2025
$53.4M
The Role of B cells in the Origin and Progression of Multiple SclerosisR35NS111644 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEPHEN L HAUSER · 2019 to 2026
$9.1M
Statistical Methods for Multilevel Multivariate Functional StudiesR01NS060910 · NINDS · JOHNS HOPKINS UNIVERSITY · PI Ciprian M Crainiceanu · 2009 to 2026
$8.3M
Harmonization of Multi-Site Neuroimaging Data from Complex Study DesignsR01MH123550 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI SHINOHARA, RUSSELL TAKESHI · 2020 to 2025
$4.0M
Advanced Statistical Analytics of MRI in MSR01NS112274 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI SHINOHARA, RUSSELL TAKESHI · 2020 to 2024
$2.8M
Interactions between Gut Microbiome and B-Cell Depletion in Multiple SclerosisK23NS107624 · NINDS · YALE UNIVERSITY · PI LONGBRAKE, ERIN · 2019 to 2023
$980k
Intramural NIH HHS ZIA NS003119NCATS NIH HHS UL1 TR001863NIMH NIH HHS R01 MH123550NINDS NIH HHS K23 NS107624NINDS NIH HHS R01 NS060910NINDS NIH HHS R01 NS112274NINDS NIH HHS R35 NS111644
6 · The paper itself

Abstract

backgroundCerebrospinal fluid (CSF) oligoclonal bands (OCB) are a diagnostic biomarker in multiple sclerosis (MS). The central vein sign (CVS) is an imaging biomarker for MS that may improve diagnostic accuracy.

objectivesThe objective of the study is to examine the diagnostic performance of simplified CVS methods in comparison to OCB in participants with clinical or radiological suspicion for MS.

methodsParticipants from the CentrAl Vein Sign in MS (CAVS-MS) pilot study with CSF testing were included. Select-3 and Select-6 (counting up to three or six CVS+ lesions per scan) were rated on post-gadolinium FLAIR* images. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value for Select-3, Select-6, OCB, and combinations thereof were calculated for MS diagnosis at baseline and at 12 months.

resultsOf 53 participants, 25 were OCB+. At baseline, sensitivity for MS diagnosis was 0.75 for OCB, 0.83 for Select-3, and 0.71 for Select-6. Specificity for MS diagnosis was 0.76 for OCB, 0.48 for Select-3, and 0.86 for Select-6. At 12 months, PPV for MS diagnosis was 0.95 for Select-6 and 1.00 for Select-6 with OCB+ status. DISCUSSION: Results suggest similar diagnostic performance of simplified CVS methods and OCB. Ongoing studies will refine whether CVS could be used in replacement or in conjunction with OCB.

Indexed as

Magnetic Resonance ImagingMultiple SclerosisOligoclonal BandsAdultBiomarkersCerebral VeinsFemaleHumansMaleMiddle AgedPilot ProjectsPredictive Value of TestsSensitivity and SpecificityBiomarkersOligoclonal Bandsbiomarkercentral vein signdiagnostic imagingmultiple sclerosisoligoclonal bands

Identifiers

PMID39234802
PMCPMC11421977

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.